Rein Therapeutics Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number: 001-38130 Rein Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)12407 N. Mopac Expy.Suite 250 #390Austin, TX(Address of principal executive offices) 13-4196017(I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code: (737) 802-1989 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 13, 2026, the registrant had 85,539,032 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION4Item 1.Financial Statements (Unaudited)4Condensed Consolidated Balance Sheets4Condensed Consolidated Statements of Operations and Comprehensive Loss5Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29PART II.OTHER INFORMATION31Item 1A.Risk Factors31Item 5.Other Information31Item 6.Exhibits31Signatures33 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q of Rein Therapeutics, Inc. (“Rein,” “we,” “us,” “our,” or the “Company”) containsforward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts,contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financialposition, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”“potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-lookingstatements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: •our plans to develop and commercialize LTI-03, including the potential benefits thereof;•our expectations regarding our ability to fund our operating expenses, our planned activities, and capital expenditurerequirements with our cash, cash equivalents and investments•our Phase 2 clinical trial of LTI-03 and our ability to re-start and complete such clinical trial, subject to obtainingadditional funding;•our decision to further delay clinical development of LTI-01 for an undetermined period of time until additional fundsare raised;•our unproven approach to drug research and development in the area of fibrotic diseases, with a focus on Caveolin-1, orCav1, related peptides, and our ability to develop marketable products;•our future clinical trials for LTI-03, whether conducted by us or by any future collaborators, including our ability toenroll patients in our clinical trials, the timing of initiation of these trials and of the anticipated results;•the success of our remediation efforts related to the material weaknesses iden